Navigation Links
Life Technologies Enters into an Exclusive License and Supply Agreement for Dynabeads
Date:7/31/2013

CARLSBAD, Calif., July 31, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced that the company has signed a long-term supply and exclusive licensing agreement  with Novartis for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer. Life Technologies will provide the company's proprietary technology, Dynabeads® CD3/CD28 CTS™, which possess unique biological properties suited to production of active, therapeutically relevant immune system cells.

The agreement includes rights to use Life Technologies' intellectual property to perform the resulting therapy, and is exclusive for use in the field of chimeric antigen receptors for the treatment of cancer.

"The collaboration with Novartis highlights the distinct capabilities that Life Technologies can provide in the therapeutic realm," said Greg Lucier, chairman and chief executive officer of Life Technologies. "Taken with our previous announcements of companion diagnostic collaborations, the current agreement demonstrates how Life is uniquely positioned to facilitate drug development through alliances with pharma."

Chimeric antigen receptor T cell based immunotherapy constitutes a novel, individualized method of combating cancers. Novartis is working to commercialize technology developed at the University of Pennsylvania that has demonstrated startling efficacy in research studies. In two 2011 publications1,2, University of Pennsylvania researchers described application of immunotherapy in three patients, all of whom experienced durable complete or partial remission of their cancers within three to four weeks of treatment. A 2013 publication in the New England Journal of Medicine described comp
'/>"/>

SOURCE Life Technologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
2. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
3. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
4. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
5. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
6. ICU Medical, Inc. Plans to "Vigorously Seek to Collect Damages" in wake of Patent Infringement Victory Over RyMed Technologies
7. BioStorage Technologies to Lead Discussion on the Value of a Comprehensive Sample Management Strategy
8. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
9. MedClean Technologies Announces 2011 Results
10. Patient Safety Technologies Reports First Quarter 2012 Results
11. Breathe Technologies Non-Invasive Open Ventilation (NIOV™) System Receives Medical Design Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... Shire plc (LSE: SHP, NASDAQ: ... Officer (CFO), has notified the Board of Directors of his decision ... career opportunity as CFO of Severn Trent plc.  James will leave ... commence a search for a new CFO immediately. Flemming ... build and lead a high-quality finance team at Shire. We are ...
(Date:10/17/2014)... CHAPEL HILL, N.C. , Oct. 17, 2014 ... healthcare landscape, the Medical Affairs function has come ... metrics, allocating resources efficiently and managing globalization.  ... at Best Practices, LLC is dedicated to providing ... issues. The Medical Affairs Consortium is a service ...
(Date:10/17/2014)... , October 17, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... disease in China ... changes in consumption concept, dietary habit, way ...
Breaking Medicine Technology:Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4Early Key Findings from the Medical Affairs Consortium Research 2China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3
... LITTLE FALLS, N.J. , May 26 CANTEL ... Andrew A. Krakauer , President & CEO, will be presenting at the ... 9:00 AM ET on Wednesday, June 9, 2010 ... a Q & A session immediately following the presentation. In addition, Mr. ...
... BOSTON , May 26 Solos Endoscopy, Inc. ... $104,774 in revenues for the first quarter ended ... the first quarter 2009, which represents a 10 percent increase. As ... in total assets. The Company has posted its financial results for ...
Cached Medicine Technology:Cantel Medical Corp. to Present at the Jefferies 2010 Global Life Sciences Conference 2Solos Endoscopy, Inc. Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009 2
(Date:10/20/2014)... San Diego, CA (PRWEB) October 20, 2014 ... regarding all the latest information from the FDA on ... consumers on October 10 not to purchase or use Sit ... Phenolphthalein. Sit and Slim II is promoted as weight loss ... , Sibutramine, removed from the market in 2010 for safety ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 ... Assisted Living Center on Oct. 14. The $11 million ... and services, and a cooked-to-order kitchen with full-service restaurant ... Akron’s premier choice for first class Assisted Living apartments,” ... “Our residents deserve the highest quality of care and ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Based ... are the only imaging assays capable of determining ... single test.  With these three dimensions of high-resolution ... to detect the widest range of disease-causing genetic ... missed by other genomic tools, including today’s advanced ...
(Date:10/20/2014)... Aliso Viejo, California (PRWEB) October 20, 2014 ... have announced the release of the Citrus theme for ... words I would use to describe the Citrus theme” Says ... been so easy to look so professional.” , Citrus comes ... . Included with the template are: four transitions for added ...
(Date:10/20/2014)... hard to imagine what it’s like to live without shoes, ... it’s a reality. And while new shoes are considered a ... barefoot on rocky terrain or sewage-lined streets just to collect ... , Buckner International's Shoes for Orphan Souls project ... encourage support for Air1 and while also providing new shoes ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... learned that you were at high risk of cancer because ... your children? A recent study at Fox Chase Cancer Center ... the next level and studied the parent perceptions of the ... be presented at the 2009 Annual Meeting of the American ...
... Chase Cancer Center uncovered a genetic pattern that may ... to the targeted therapy imatinib mesylate (Gleevec). Moreover, ... in order to make these tumors respond more readily ... in the laboratory of Andrew K. Godwin, PhD, at ...
... new pharmaceutical products in the pipeline combined with new ... the rare disease community, a senior Food and Drug ... by the National Organization for Rare Disorders (NORD).The blockbuster ... director of the Center for Drug Evaluation and Research ...
... 14 Hanger Orthopedic Group Inc. (NYSE: ... in the S&P SmallCap 600 after the close of trading ... acquired by privately held TriNet Group, Inc. in a transaction ... and post any relevant updates on its website: ...
... MedServe, Inc., a private company, today announced that it ... Stericycle, Inc. (Nasdaq: SRCL ) for $185 ... Avista Capital Partners, Chrysalis Ventures and Murphree Venture Partners ... collection, transportation, treatment and disposal of medical waste, hazardous ...
... ImQuest Bio and Arisyn jointly presented important ... inhibitor of hepatitis C virus (HCV) replication, at the 13th ... presentation highlighted the ability of PG301029 to potently suppress the ... potential mechanism of antiviral action through the selection of a ...
Cached Medicine News:Health News:Should parents share the results of BRCA1/2 genetic testing with their children? 2Health News:Gene signature may predict patient response to therapy for gastrointestinal stromal tumors 2Health News:NORD Sponsors Rare Disease Summit 2Health News:Standard & Poor's Announces Changes to U.S. Index 2Health News:MedServe to be Acquired by Stericycle for $185 Million 2Health News:MedServe to be Acquired by Stericycle for $185 Million 3Health News:ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference 2
Claes Shielded Retinotomy Scissors, Vertical...
... DxSelect is intended for qualitatively detecting antibodies ... serum. The test is indicated for testing ... an aid in the presumptive laboratory diagnosis ... intended for self-testing, and this test is ...
... Indirect immunofluorescent antibody (IFA) test for ... IgG antibodies to St. Louis Encephalitis virus ... Equine Encephalitis virus (EEE), and California Encephalitis/La ... 8-well slides with fixed individual spots of ...
... immunofluorescent antibody (IFA) test ... semi-quantitation of human serum ... viral capsid antigen (VCA). ... 12-well slides, FITC IgG ...
Medicine Products: